Akebia Therapeutics Inc (NASDAQ:AKBA)
| 12.30 Delayed Data As of 3:59pm ET |  +0.145 / +1.19%Today’s Change | 2.99 Today|||52-Week Range 13.17 | +94.54% Year-to-Date |
Latest AKBA News | Press Releases
No recent news for Akebia Therapeutics Inc.
Today’s Trading
| Previous close | 12.15 |
| Today’s open | 12.14 |
| Day’s range | 11.73 - 12.40 |
| Volume | 190,220 |
| Average volume (3 months) | 1,647,274 |
| Market cap | $1.7B |
Data as of 3:59pm ET, 05/27/2020
Growth & Valuation
| Earnings growth (last year) | +4.52% |
| Earnings growth (this year) | +38.19% |
| Earnings growth (next 5 years) | +15.80% |
| Revenue growth (last year) | +61.26% |
| P/E ratio | NM |
| Price/Sales | 2.23 |
| Price/Book | 3.75 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LGNDLigand Pharmaceutica... | -1.21 | -1.14% |
| ZYMEZymeworks Inc | +0.80 | +2.09% |
| TBPHTheravance Biopharma... | -1.58 | -5.92% |
| ZGNXZogenix Inc | -0.54 | -1.78% |
Data as of 4:00pm ET, 05/27/2020
Financials
| Next reporting date | August 5, 2020 |
| EPS forecast (this quarter) | -$0.48 |
| Annual revenue (last year) | $335.0M |
| Annual profit (last year) | -$279.7M |
| Net profit margin | -83.48% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
